template_about
Our VISION
To make nanopolymer drug delivery a proven, safe, and effective solution accessible worldwide, while enjoying the journey of developing life-saving innovations.
Our MISSION
Save patients’ lives with nanotechnology
Pioneering the Interleukin-12 prodrug Axis
Broad applicability of Red Arrow prodrug technology including:
Small peptide to antibody full chain
Cationic protein to anionic protein
Lead asset – RA001 – IND planned for 2027
Based on novel technologies developed by a pioneer of nanomedicine, Prof. Dr. Horacio Cabral from the University of Tokyo
Main Investors: The University of Tokyo Edge Capital (UTEC), Beyond Next Ventures (BNV)